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Bactericidal antibody is required for direct complement-mediated killing of 
most pathogenic gram-negative bacteria. Although it has been implicitly assumed 
that bactericidal  antibody functions by increasing complement activation and 
deposition on the bacterial surface, this assumption may not be valid. We have 
shown previously (1) that bactericidal IgG increases the bactericidal efficiency of 
C5b-9 for the serum-resistant Escherichia coli 0111 strain 12015, without increas- 
ing the extent of C5b-9  deposition.  Bactericidal  IgG markedly increased the 
percentage of the total C5b-9 bound to E.  coli 011 1 that was inserted into the 
outer membrane in a salt- and protease-resistant form (2). The effect of IgG was 
mediated at a  step before C5  convertase formation since the addition of IgG 
after the C5 convertase was formed, but before the C5b-9  was deposited, did 
not kill bacteria (3). 
These experiments suggested that bactericidal IgG was changing either the 
location of complement activation or the molecular conformation of C5b-9  on 
the bacterial surface. We have now extended these studies by showing that (a) 
nearly one-fifth of the total C3 that is bound in the presence of antibacterial IgG 
binds covalently to  the antibody molecule and (b)  complexes of C3b-IgG are 
three- to  fourfold more effective than  IgG in  presensitizing strain  12015  for 
complement-mediated killing. Formation of C3b-IgG complexes may be critical 
for effective killing of some gram-negative bacteria by the serum-complement 
system. 
Materials and Methods 
Buffers.  The following buffers were used in these experiments:  Hanks' balanced salt 
solution  (HBSS)  ~ containing 0.15  mM CaCI2 and  1.0  mM MgCi2 (HBSS++); low ionic 
strength (# =  0.060) dextrose-gelatin  veronal-buffered  saline with 0.15  mM CaC12 and 
1.0 mM MgCl~ (DGVBS++); isotonic gelatin veronal-buffered  saline with 0.15 mM CaCI2 
and 1.0 mM MgCl~ (GVBS++). 
Bacterial  Strains.  E.  coli 0111B4  (ATCC  12015), E.  coli J5 (kindly provided  by Dr. 
Elizabeth Zeigler, University of California, San Diego, CA), and Salmonella minnesota  Re 
595  (provided  by  Dr.  Jack  Hawiger,  Boston,  MA)  were  the  bacterial  strains  used. 
Characteristics of these strains are as outlined previously (3). 
t Abbreviations used in  this paper:  Abs PNHS, absorbed PNHS; avidin-Seph, avidin covalently 
coupled to Sepharose 4B; C8D, C8 deficient;  HBSS, Hanks' balanced salt solution; HBSS  ÷+, HBSS 
containing CaC12 and MgCI~; LPS, lipopolysaccharide;  NPGB, p-nitrophenyl  p-guanidinobenzoate; 
O-Ag, O antigen;  PBS, phosphate-buffered  saline; PNHS, pooled, normal  human  serum; SDS-PAGE, 
sodium dodecyl  sulfate-polyacrylamide  gel electrophoresis. 
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Bacteria were grown in trypticase soy broth at 37°C with continuous agitation to mid- 
log phase for use in experiments.  Cells were washed in HBSS  +÷ at room temperature or 
4 °C and adjusted to the desired concentration spectrophotometrically. 
Serum.  Serum  was  obtained  from  seven  normal  volunteers,  pooled,  and  frozen  in 
aliquots at -70°C  (PNHS). Serum samples from a  patient with a  congenital absence of 
C8 (C8D) and from a patient with acquired hypogammaglobulinemia were also used. For 
some experiments,  serum was absorbed with strain  12015 before use to remove natural 
antibody.  1 ×  101° organisms were mixed with 4 ml of serum at 0°C for 30 rain, and the 
bacterial pellet was removed by centrifugation at 20,000 g for 15 rain at 0°C (1).  Serum 
absorbed in this fashion (Abs PNHS) lost <15% of the initial C3 hemolytic activity. 
Antibody Preparation.  The IgG fraction of rabbit antiserum to the lipopolysaccharide 
and O  antigen (O-Ag) capsule of 12015 (4) was prepared and characterized as described 
earlier (1).  A portion of the IgG preparation was radiolabeled with l~SI-Na (New England 
Nuclear, Boston, MA) using Iodobeads (Pierce Chemical Co., Rockford, IL) to a specific 
activity of 9.87  ×  105 cpm/#g. Another portion of purified IgG was biotinylated with n- 
hydroxysuccinimide biotin (Calbiochem-Behring Corp.,  La Jolla, CA) with reaction con- 
ditions identical to those previously described for biotinylation of C3 (5). Biotinylated IgG 
contained an average of 1.8 biotin residues per molecule. Biotinylated IgG had aggluti- 
nation  and  bactericidal  titers  for  12015  that  were  unchanged in comparison to native 
IgG. 
Monospecific antiserum to C3 was raised in goats. This antiserum recognizes determi- 
nants on native C3 and on all cleavage fragments of C3: C3b, iC3b, C3c, and C3dg. The 
IgG fraction of goat anti-C3 was coupled by cyanogen bromide linkage to Sepharose 4B 
using standard techniques. Avidin (Calbiochem-Behring Corp.) was covalently coupled to 
Sepharose 4B (avidin-Seph) as previously described (5, 6). 
Complement Component Purification.  Human C3 was purified to homogeneity by minor 
modifications of the procedure of Hammer et al.  (7);  C3 was radiolabeled  with  l~SI-Na 
(Amersham  Corp.,  Arlington  Heights,  IL) using Iodobeads (Pierce  Chemical Co.) to a 
specific radioactivity of 2.8 ×  105 cpm/#g. Iodination resulted in <20% loss of hemolytic 
activity. 
Distribution  of C3 and IgG  on E.  coli 12015.  The  distribution  of IgG on the  O-Ag 
capsule compared with that on the outer membrane of 12015 was determined before and 
after serum incubation. Strain  12015 was suspended to an OD600 of 1.5 in HBSS  ÷+, then 
incubated with  125I-IgG at 50 #g/ml for 20 min at room temperature.  Organisms were 
washed twice. An aliquot of cells bearing  ~2~I-IgG was removed, passed twice through a 
French press cell at  16,000 lb/in 2, and processed as described below. The remainder of 
the presensitized organisms were suspended to the original volume in HBSS  ++, then mixed 
vol/vol with 20% absorbed (Abs) C8D. The suspension was incubated for 60 min at 37 ° C, 
and the organisms were washed twice and passed through a French press cell as described 
above. 
The French press lysates from samples before and after serum incubation were centri- 
fuged at  113,000 g  for 2  h  to separate  the outer membrane (sediment) from the O-Ag 
capsule (supernatant) as described (4, 6).  Distribution of ~2~I-IgG in the outer membrane 
and O-Ag capsule fractions was determined with a gamma scintillation counter. In control 
experiments, we found that <5% of ~5I-IgG centrifuged under identical conditions in the 
absence of a bacterial lysate was recovered at the bottom of the tube. 
Distribution of C3 on the O-Ag capsule compared with that on the outer membrane of 
12015 was also determined.  Strain  12015 at OD600 1.5 in HBSS  ++ was presensitized with 
50 #g/ml of unlabeled IgG for 20 rain at room temperature,  then incubated for 60 rain 
at  37°C  in  a  final  concentration  of 10%  Abs C8D containing  125I-C3. The cells  were 
washed, and the  ~5I-C3 that was associated with the outer membrane and O-Ag capsule 
was measured as described above. 
Determination of C3 Binding to Biotinylated IgG on 12105 During Serum Incubation.  We 
determined the extent of covalent attachment of C3 to biotiny!ated IgG on 12015 during 
incubation in serum. Strain  12015 was suspended to OD600 1.5 in HBSS  +÷. Aliquots of 2 
ml were incubated for 20 rain at room temperature with 300 #g/ml of either biotinylated JOINER  ET  AL.  879 
or nonbiotinylated  IgG.  Cells  were washed  once in  HBSS  ÷+,  then resuspended  to the 
original volume in HBSS  ++. Presensitized organisms were mixed with an equal volume of 
either  20%  C8D  or  20%  A56°C  C8D  in  HBSS  +÷  containing  15  /~g/ml  of  ~25I-C3. 
Suspensions were incubated for 60 rain at 37°C with agitation. Aliquots of 150 ttl were 
removed, applied to microcentrifuge tubes containing 1 ml of cold HBSS  ÷÷, and centri- 
fuged for 5 min at 12,500 g. The supernatant was removed and the counts per minute of 
1251 within the bacterial pellet were determined with a gamma scintillation  counter. The 
total number of molecules of C3 bound per colony-forming  unit within the bacterial pellet 
was determined as indicated earlier (8). The remainder of the samples were washed twice 
in HBSS  ++, and the washed pellets were solubilized in 1 ml of 1% sodium dodecyl sulfate 
(SDS) at  100°C for 10 rain.  Insoluble material was removed by centrifugation for 5 min 
at  12,500 g.  The supernatants were diluted with  2 vol of 0.01  M Tris buffer, pH 8.5, 
containing 0.25 M NaCI, 0.3% SDS, and 1% Triton X-100 (buffer A) and applied to 200 
~1 of  packed avidin-Seph resin. Buffer A was shown in preliminary experiments to minimize 
nonspecific binding of ~2~I-C3 to avidin-Seph in  comparison with  buffers containing a 
lower  concentration  of NaCI  or  different  ionic  (deoxycholate) or  zwitterionic  [SB~2, 
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-  1-propanesuifonate)] detergents. Mix- 
tures  were  incubated  overnight at  room temperature.  Avidin-Seph was  washed  three 
times with buffer A and the '25I-C3 bound to the resin was determined by counting in a 
gamma scintillation  counter. 
Preparation of C3b-IgG.  Covalent complexes of C3b-IgG were prepared with minor 
modifications of the procedure described by Fries et al. (9). To 1 ml of IgG at 45 mg/ml 
in phosphate-buffered saline (PBS) was added 370 #g of 125I-C3 (IgG-to-C3 ratio of 120:1). 
N-tosyI-L-phenylalanine chloromethyl ketone (TPCK)-treated trypsin (Worthington Bio- 
chemical Corp., Freehold, N  J) was added to achieve a trypsin-to-C3 ratio of 0.02:1.0 by 
weight. The sample was incubated for 8 rain at  37°C, followed by the addition of the 
protease inhibitor p-nitrophenyl p-guanidinobenzoate (NPGB) (Sigma  Chemical Co., St. 
Louis, MO) to 25/~M.  Solid NaCI was added to achieve a final concentration of 1 M, and 
one part of 2.0 M acetate buffer, pH 5.6, was added to 19 parts of the C3-IgG mixture 
to reach a  final  of 0.1  M acetate.  The sample  was applied to a  1.5  ×  100 cm column 
containing Ultrogel AcA-34 (LKB Instruments, Inc., Gaithersburg, MD) and chromato- 
graphed in 1 M NaCI, 0.1  M acetate buffer, 25/~M  NPGB, pH 5.6. The elution profile is 
shown in Fig.  1A. Pool 1 was concentrated in a diafiltration cell (Amicon Corp., Danvers, 
MA) using a PM 30 membrane, and dialyzed against 90 mM NaCI, 20 mM PO4, 25 #M 
NPGB, pH  7.0. The dialyzed sample was applied  to QAE Sephadex A-50 in the same 
buffer containing 0.002% gelatin and 0.01  M EDTA, and the column was eluted with a 
linear salt  gradient from 90 to 250 mM  NaCI in  20 mM  PO4,  25 ttM  NPGB,  0.002% 
gelatin,  pH  7.0.  Pools  1  and  2  were  made  as  indicated  (Fig.  1A),  concentrated  by 
diafiltration, dialyzed against PBS, and analyzed as described below. 
Characterization of Pools  from QAE Sephadex A-50.  Pools from QAE Sephadex A-50 
were tested by double-diffusion analysis in  1% agarose gels containing antisera to human 
C3 and to rabbit IgG (Cappel Laboratories, Cochranville, PA). 
Samples eluted from UItrogel AcA-34 (Fig.  1  A) and from QAE Sephadex A-50 (Fig. 
1B)  were  analyzed  by  4-8%  gradient  SDS-polyacrylamide gel  electrophoresis  (SDS- 
PAGE), as previously described (9). Gels were dried and autoradiography was done with 
Kodak XAR-5 film and Dupont Cronex Lightning Plus intensifying screens. 
Pools from QAE Sephadex A-50 were analyzed by sucrose density gradient ultracen- 
trifugation. Before application to sucrose density gradients, samples  of ~2~I-IgG  and *~sI- 
C3b-IgG were centrifuged at 178,000 g for 20 rain at room temperature in an air-driven 
ultracentrifuge (Beckman Instruments,  Inc., Palo Alto, CA).  The top 50%  of the tube 
was removed, and 25/~1 was applied to a linear  10-40% sucrose gradient in PBS in 2 × 
0.5-in polyaliomer tubes (Beckman Instruments). Samples were centrifuged for  18 h at 
4°C in an SW 50.1  rotor at 35,000 rpm in a Beckman L8 ultracentrifuge. Three-drop 
fractions were collected using a gradient fractionator (Bio-Rad Laboratories, Richmond, 
CA).  Radioactivity within  gradient  fractions was determined  by counting in  a  gamma 
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and included ~25I-C9 (4.5 S), ~25I-C3 (8.0 S), and l~I-fibronectin (13.6 S), the latter kindly 
supplied by Dr. John Bohnsack, NIH, Bethesda, MD. Peak tubes within the 125I-C3b-IgG 
and ~e~I-IgG gradient peaks were dialyzed against PBS, and the remainder of the gradient 
peaks were pooled and dialyzed against PBS and stored at 4°C. Most subsequent experi- 
ments  with  ~25I-C3b-IgG and  l~sI-IgG  prepared  from  sucrose  density  gradients  were 
performed within 3 d of  collection of the pools to minimize reaggregation within monomer 
preparations. 
Serum Bactericidal Assays with IgG and C3b-IgG.  Killing of 12015 was measured in Abs 
PNHS after presensitization with ~25I-IgG or ~sI-C3b-IgG. To 100-#i  aliquots of strain 
12015 (at OD600 0.300 in HBSS  ÷+) were added 20-#1 samples containing either 36,  180, 
or 900 ng of t25I-IgG or 80, 400, or 2000 ng of 12~I-C3b-IgG, an equimolar amount. 
Before use for presensitization, both ~25I-IgG and ~25I-C3b-IgG were centrifuged for 20 
rain at 178,000 g in an air-driven ultracentrifuge. The top 50% of the sample was removed 
for subsequent presensitization, and the remainder of the sample was discarded. -40% of 
the applied ~25I counts were recovered in the top 50% of the centrifuge tube for both 
125I-IgG and 125I-C3b-IgG. 
For some experiments, 12015 was presensitized with samples of ~2~I-IgG and ~25I-C3b- 
IgG  from  sucrose density gradients.  When  pooled  samples  from  the  sucrose density 
gradient profile were used, 12015 was presensitized with 30, 150, and 750 ng of  I-IgG 
and with 55, 275, and 1,375 ng of  I-C3b-IgG. Alternatively, 12015 was presensitized 
with the same amounts of C3b-IgG and IgG from the peak tubes of the sucrose density 
gradient profile. Mixtures were incubated at room temperature for 40 rain, then divided 
into two aliquots of 50 #1 each. An equal volume of 20% Abs PNHS in HBSS  ÷+ was added 
to one aliquot and 50 tA of A56°C Abs PNHS in HBSS  ÷÷ was added to the other aliquot. 
Samples were incubated at 37 ° C for 60 rain, and viable bacterial colonies were quantitated 
as previously described. 
Quantitative binding studies were done to determine the amount of ~2~I-IgG and l~sI- 
C3b-IgG bound to 12015 during the presensitization step. 30 ~1 of the reaction mixture 
was removed, applied to microcentrifuge tubes containing 1 ml of HBSS  ++, and centri- 
fuged for 5 rain at 12,500 g. The supernatant was aspirated and the pellet was counted 
in a gamma scintillation counter. Nonspecific binding of ~I-IgG and 225I-C3b-IgG was 
determined in tubes containing a 50-fold excess of unlabeled IgG or IgG and C3b. 
Results 
Distribution  of C3 and  IgG  on  12015.  The  distribution  of IgG  and  C3  on 
12015 was determined after serum incubation.  82% of the  125I-IgG that bound 
to  12015  was distributed with the supernatant (O-Ag) fraction of presensitized 
12015 after lysis in a French press cell and separation of O-Ag  capsule and outer 
membrane fractions (Table I). The distribution of l~I-C3b on the O-Ag capsule 
and  outer  membrane  of  12015  was  also  determined.  Total  C3  deposition  on 
12015 was increased by 66% after presensitization with bactericidal IgG (Table 
I). The partitioning of C3 was similar to that of IgG. ~80% of the C3 deposited 
on 12015 was in the O-Ag capsule fraction, in both the presence and absence of 
bactericidal  IgG.  The  remaining  20%  of the  C3  was  deposited  on  the  outer 
membrane.  These results showed  that  bacterial  IgG  did not  function by redi- 
recting a significant fraction of total C3 deposition from the O-Ag capsule to the 
outer membrane. 
Binding of C3 to lgG  on E.  coli  12015.  We next investigated  the  possibility 
that  C3  was  deposited  on  the  IgG  molecule  itself during  serum  incubation. 
Results showed that nearly one-fifth of the x25I-C3 that deposited on presensitized 
12015 attached covalently to antibody (Table H).  Furthermore, this value may 
be an underestimate of the percentage of C3 attached to IgG: only 86% of a25I- JOINER  ET  AL.  881 
TABLE  I 
Distribution  of lgG and C3 on 12015 
Component  n 
Total No. of  Distribution after French 
molecules  press lysis 
per CFU 
(x 10  4) pre- 
ceding  In pellet  In superna- 
French press  tant 
lysis 
% 
125I-IgG  2  3.8 --+ 1.3"  18.0 -- 3.4  82.0 --+ 3.4 
1~5I.C3 
Without IgG  2  4.1  -+ 0.7  21.6 --- 6.4  78.4 -  6.4 
With IgG  2  6.8 -  0.3  18.7 +  5.1  81.3 -  5.1 
*  Mean  +  SD.  The  molecules of IgG  and  C3  bound  to  serum-treated 
12015  were  measured  under  conditions  described  in  Materials  and 
Methods.  The  distribution  of these  molecules  was  determined  after 
French press lysis of the cells. 
TABLE  II 
Binding of C3 to IgG on 12015 
Antibody  Serum 
Percent of 1~5I-C3 
on  12015 binding 
to avidin-Seph 
Biotinyl IgG  10% C8D  18.4 +  2.1" 
Biotinyl IgG  10%  A56°C C8D  1.0 +  0.3 
IgG  10% C8D  0.5 _+ 0.3 
None  10% C8D  0.8 _+ 0.4 
* Mean _  SD of two experiments performed in duplicate.  Bacteria were 
presensitized with the indicated antibody source, then incubated in C8D 
serum containing M~I-C3. Cells were solubilized in  1% SDS and applied 
to avidin-Seph, and the percentage of list-C3 bound was determined. 
biotinyl-IgG on  12015 bound to avidin-Seph under similar conditions (data not 
shown), suggesting that recovery of IgG on avidin-Seph was incomplete. Fur- 
thermore, ~ 11% of the total 125I-C3 deposited on 12015 was bound nonspecifi- 
caily (data not shown). Therefore, as much as 24.0% (18.4%  ×  100/86  ×  100/ 
89) of specifically bound C3 may attach to IgG. Since the enhanced C3 deposition 
on 12015 mediated by IgG accounts for 40% of the total C3 bound, these results 
imply that at least half of the additional C3 deposited on 12015 as a consequence 
of presensitization with IgG is covalently bound to IgG. 
Preparation of C3b-IgG.  The results from the above experiments suggested 
that formation of C3b-IgG complexes might be critical to the action of bacteri- 
cidal antibody. To study this possibility, we prepared complexes of l~5I-C3b-IgG. 
Details of the purification scheme are provided in Materials and Methods. The 
column elution  profiles are shown  in  Fig.  1,  along  with a  4-8%  SDS-PAGE 
autoradiogram of selected samples from the purification process. The final 12~I- 
C3b-IgG preparation for use in experiments was pool 1 from QAE Sephadex A- 
50. Three major iodinated bands were apparent by SDS-PAGE analysis of pool 882  BACTERICIDAL  ACTIVITY OF  C3b-IgG 
FIGURE  1.  Preparation  of C3b-lgG. (A) Elution profile of C3b-IgG preparation  on Ultrogel 
AcA-34 in  1 M NaCI, 0.1  M acetate, and 25 ~M NPGB, pH 5.6. Pool 1 was concentrated, 
dialyzed, and applied to QAE Sephadex. (B) Elution profile of pool 1 from UItrogel AcA-34 
on  QAE  Sephadex  A-50 in  90  mM  NaC1, 20  mM  NaPO4, and  25  tLM  NPGB, pH  7.0, 
containing 0.002% gelatin. A linear NaCl gradient  from 90 to 250 mM was applied. Pools 1 
and 2 were prepared as indicated and analyzed by SDS-PAGE. (C) 4-8% SDS-PAGE autora- 
diography of pools from Ultrogel AcA-34 and QAE Sephadex A-50. 
1  (Fig.  1 C).  A  band  migrating  at  110,000  daltons  is  compatible  with  the 
noncovalently  linked,  free  a'  chain  of C3b,  and  a  band  migrating  at  75,000 
daltons is compatible with the/3 chain of both free C3b and the C3b within C3b- 
IgG complexes.  The  most prominent  band  in  the  Sephadex  A-50  QAE pool  1 
migrated at ~ 180,000  daltons.  This location  is most consistent with a  covalent 
complex between the ~' chain of C3b and the heavy chain of IgG, as previously 
reported  by others  (9-12).  A  less intense  band  of 140,000  daltons  presumably 
represents covalent attachment of the a' chain of C3b to the light chain of IgG. JOINER  ET  AL.  883 
By densitometric scanning of a  less intensively exposed autoradiogram,  83% of 
the total a' activity was contained in the C3b-heavy chain complex. 
Three separate lines of evidence suggested that minimal unbound IgG contam- 
ined pool  1.  First,  IgG  did  not  bind  to  QAE  Sephadex  A-50  and  separated 
broadly from pools 1 and 2 (data not shown). Second, the agglutination titers of 
C3b-IgG and IgG were identical when equivalent inputs of IgG were compared 
(data not shown). Third, as discussed below, binding of 125I-IgG and  125I-C3b- 
IgG to 12015 was equivalent at equimolar inputs of the iodinated moiety. 
We  have  shown  in  other  experiments  (data  not  shown)  that  up  to  60% 
incorporation  of  125I-C3 into  JeSI-C3b-IgG  can  occur  and  that  the  specific 
radioactivity of 125I-C3b  is not changed significantly (<15%)  in comparison to 
125I-C3. Therefore, IgG content within 125I-C3b-IgG can be calculated based on 
the specific activity of ~25I-C3b within the complex. This finding was independ- 
ently confirmed by (a) total protein determination on isolated 125I-C3b, isolated 
IgG, and on an aliquot of the 125I-C3b-IgG used in our experiments, which was 
purified without the use of gelatin; and (b)  radial  immunodiffusion assays (for 
gelatin-containing samples) on 125I-C3b-IgG and purified 125I-C3b in plates de- 
tecting C3c antigen.  Specific activity (cpmh~g) of C3c antigen in  ~25I-C3b-IgG 
and uncomplexed 125I-C3b was identical. 
Bactericidal Activity of l25I-IgG and 125I-C3b-IgG.  We compared the bactericidal 
activity of 125I-IgG and 125I-C3b-IgG for 12015 in 10% Abs PNHS. At equivalent 
molar inputs of IgG,  presensitization  with  l~sI-C3b-IgG led to more extensive 
killing of 12015 than that with 125I-IgG alone (Fig. 2). In three separate experi- 
ments, the concentration of IgG required for 0.8 log~0 killing was 8.2-9.6 times 
greater than the concentration of IgG within lzsI-C3b-IgG required for 0.8 logl0 
killing.  These results  suggested that  IgG within C3b-IgG  was markedly more 
effective than IgG alone in presensitizing 12015 for serum killing. 
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FIGURE 2.  Bactericidal activity of C3b-IgG and IgG for  12015 in  10% Abs PNHS.  12015 
was  presensitized with increasing and equimolar concentrations of either IgG or  C3b-IgG 
before incubation in  10% Abs PNHS.  Log~0 killing was determined as described in Materials 
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TAaLE III 
Binding of 1~5I-C3b-IgG and l~5I-IgG to 12015 
IgG input 
Molecules  per CFU (xl03) 
C3b-lgG  IgG 
ng 
750  8.0 _+ 2.2*  10.5 + 4.0 
150  1.7 + 0.5  1.8 + 0.8 
* Mean + SEM for three experiments  performed in duplicate. The bac- 
teria were sensitized  with equimolar  inputs of 12~l-C3b-lgG or 1251-IgG, 
and the number of molecules  of each that bound to the organisms  was 
determined. 
Binding of 1251-C3b-[gG and  125I-IGG to  12015.  We tested the possibility that 
enhanced bactericidal activity of 125I-C3b-IgG  relative to  125I-IgG represented 
more efficient binding of ~25I-C3b-IgG to 12015 during the presensitization step. 
Direct  measurements  of  I25I-C3b-IgG  and  125I-IgG binding  to  12015  were 
performed in conjunction with the serum killing assays.  Equivalent numbers of 
125I-C3b-IgG and l~sI-IgG molecules were bound per colony-forming unit (CFU) 
at equivalent molar inputs of IgG (Table III). This observation was true for both 
the  125I-IgG and  125I-C3b-IgG  monomer preparations  (Table III) prepared as 
described below  by  sucrose  density gradient ultracentrifugation, and  for the 
preparations used in the experiment shown in  Fig.  2 (data not shown). Nearly 
fivefold more molecules of 125I-C3b-IgG and 125I-IgG were bound with a fivefold 
increase in input (150 to 750  ng) of IgG. Accurate determination of 125I-C3b- 
IgG and 125I-IgG binding at inputs of 30 ng was not feasible. 
Sucrose Density  Gradient Analysis of 125I-C3b-IgG and 125I-IgG.  Aggregate for- 
mation  within  the  ~25I-C3b-IgG  preparation  could account  for the  enhanced 
bactericidal activity of ~25I-C3b-IgG in comparison with ~25I-IgG. In the experi- 
ments described above, large aggregates were removed from both the az5I-C3b- 
IgG  and  ~25I-IgG preparations  by  ultracentrifugation  before  use.  However, 
smaller oligomeric aggregates might not have been removed. Therefore, isoki- 
netic 10-40%  sucrose density gradient ultracentrifugation of 125I-C3b-IgG  and 
lzsI-IgG was performed to prepare putative monomer pools (Fig. 3). In addition, 
an aliquot was removed from the peak tube of the  ~25I-C3b-IgG  and  ~I-IgG 
peaks before collection of the monomer pools.  Only a small percentage (<3%) 
of the samples applied  to  the gradient contained aggregates large enough to 
sediment to  the  bottom  of the  gradient,  making  it  unlikely that  aggregates 
accounted for the enhanced bactericidal activity of ~25I-C3b-IgG in comparison 
with  IgG  (Fig.  2).  This presumption  was directly tested in  the next series of 
experiments. 
Serum Bactericidal  Assay with Sucrose Density Gradient Pools.  Pools containing 
12~I-C3b-IgG and 125I-IgG monomers from sucrose density gradients were used 
to presensitize 12015 for serum bactericidal assays. At equivalent molar inputs 
of IgG, killing with 125I-C3b-IgG significantly exceeded killing with 125I-IgG (Fig. 
4).  At IgG inputs of 150  ng or less,  12~I-C3b-IgG  was three- to fourfold more 
efficient than 125I-IgG at mediating bactericidal activity. The difference in logl0 JOINER  ET  AL. 
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Results shown represent mean _-!-  SD for three experiments performed in duplicate. 
killing  at  an  input  of  750  ng  was  also  statistically  significant.  These  results 
indicate  that  monomeric  l~5I-C3b-IgG  is  more  effective than  monomeric  l~I- 
IgG in presensitizing  12015 for serum killing. 886  BACTERICIDAL ACTIVITY OF  C3b-IgG 
Discussion 
Bactericidal  IgG markedly enhances  alternative  complement pathway-medi- 
ated killing of E. coli 12015, although deposition of C3 is only modestly increased 
in the presence of the antibody. We show here that up to one quarter of deposited 
C3 binds covalently to the bactericidal antibody molecule. These findings raise 
the  possibility  that  C3b-IgG  is  particularly  effective at  mediating  the  serum 
bactericidal  reaction.  To test  this  presumption,  C3b-IgG complexes were pre- 
pared.  These  complexes were  found  to  have  markedly  enhanced  bactericidal 
activity, since three- to fourfold fewer C3b-IgG molecules than  IgG molecules 
were required to bind to  12015 to render the strain serum sensitive. Since C3b 
deposits on intact IgG molecules on 12015 during serum incubation of antibody- 
coated bacteria, it is possible that only IgG-bearing C3b can mediate the serum 
bactericidal reaction for 12015. 
Conceptually, the enhanced bactericidal activity of C3b-IgG may be due to a 
change in the number,  localization,  or form of deposited C3b-9.  However, our 
previous experiments with  this organism  indicated  that  IgG enhanced  the bac- 
tericidal  efficiency of C5b-9  without  increasing  the  number  of bound  C5b-9 
complexes.  The  present  data  suggest  that  IgG does not  redirect  complement 
deposition to a different location on the bacterial surface, since the distribution 
of C3b between capsule and outer membranes was unchanged.  It is more likely 
that  IgG changes the organization  of C5b-9 on the outer membrane.  C3b-IgG 
complexes may serve as an efficient focus for C5 convertase formation (13,  14) 
since C3b bound to  IgG is relatively protected from inactivation  by factors  H 
and I (9). Clustering of C5b-9 complexes around the site of IgG deposition could 
result, which could, in turn, influence the capacity of deposited C5b-9 to disrupt 
the  rigid  bacterial  outer  membrane.  In  fact,  in  the  absence  of antibody,  the 
deposited C5b-9 on E. coli 0111 does not insert into hydrophobic domains of the 
outer membrane whereas, in the presence of antibody, such insertion does occur 
(2). 
It is also possible that  covalent complexes of C3b-IgG alter  the form rather 
than  the  localization  of the  C5b-9 complex.  The  stoichiometry of C9  binding 
within C5b-9 alters the bactericidal efficiency of the complex. We have recently 
shown (15) that an average C9/C5b-8 ratio of at least 3.3:1 is required for killing 
of the rough E.  coli strain J5, and maximal  killing is not achieved until the C9/ 
C5b-8 ratio  exceeds 6:1.  A  C9/C5b-8  ratio  of 1:1  does not result  in  bacterial 
death.  Previous  experiments  (1)  showed  that  the  average  C9/C5b-8  ratio  on 
12015  was the same (5.7-6.4  to  1) in  the presence or absence of bactericidal 
IgG. However, a change in the C9/C5b-8 ratio of the complexes associated with 
C3b-IgG might  have been  undetectable since these complexes represent  a  mi- 
nority of the total C5b-9 deposited on the cell. 
The bactericidal activity of IgG for 12015 is mediated through the alternative 
complement  pathway  (1).  Antibody-dependent,  alternative  pathway-mediated 
killing of gram-negative bacteria is well documented (16-19), but C3b deposition 
on antibody was not examined in previous experiments. Covalent binding of C3 
to antibody  has  been  demonstrated  during  alternative  pathway  activation  by 
immune  complexes (9,  10), and  it is postulated but not proven  that  this  C3  is 
critical  for the  resultant  dissolution  of the  complex.  Moore et al.  (20) showed JOINER  ET  AL.  887 
that  immune  rabbit  IgG  enhanced alternative  pathway  activation  by  mouse 
erythrocytes by increasing the efficiency of C3b deposition and C5  convertase 
formation without changing the extent of C3 consumption. The same authors 
suggested that C3 may have been deposited on the antibody molecule (21), but 
this presumption was not directly tested. In contrast, Schenkein and Ruddy (22) 
could not demonstrate C3 binding to IgG on zymosan during antibody-mediated 
acceleration of alternative pathway activation. 
Antibody appears to be a particularly good acceptor for C3b deposition (23). 
The site of C3b deposition on the IgG molecule has been examined. Gadd and 
Reid  (10)  demonstrated that  during activation  of the alternative pathway by 
immune aggregates containing rabbit IgG, the a' chain of C3b binds covalently 
to one or two sites in the Fd portion of the heavy chain of IgG. Similar results 
were reported by Takata et al.  (11).  In both of these systems, C3b deposition 
was mediated by the alternative complement pathway. Brown et al. (1"2) reported 
that  C3b  binds  to  both  heavy and  light chains of rabbit  IgG on Streptococcus 
pneumoniae when complement is activated through the classical  pathway using 
purified C1,  C4,  C2,  and C3  (11).  Arnaout and colleagues (24) demonstrated 
light chain uptake of C3b using trypsin cleavage of C3. We did not examine the 
immunoglobulin chains bearing C3b when C3b-IgG complexes were formed on 
12015 during serum incubation. However, the highly efficient C3b-IgG complex 
used in  these experiments contained C3b  that attached predominantly to  the 
heavy chain of the rabbit IgG. This result using the IgG fraction of bactericidal 
antiserum is in accord with the findings of Fries et al. (9), who prepared complexes 
of C3b and human IgG by trypsinization. 
Isotypes of IgG that serve as good acceptors for C3b deposition may be more 
effective bactericidal and opsonic molecules than isotypes which are inefficient 
C3 acceptors. Similarly, monoclonal antibodies from various animal species, if 
used for passive protection,  may vary in their bactericidal activity, depending 
not  only on  their  antigenic  specificity but  also  on  their  capacity to  serve as 
acceptors for C3b deposition. These theoretical possibilities are important in the 
consideration of vaccine development. Moreover, the ability to prepare C3b-IgG 
complexes that have greatly increased cytocidal efficiency may have important 
clinical implications. 
Summary 
The mechanism was sought by which bactericidal IgG for E. coli 0111  (strain 
12015)  increases the bactericidal  efficiency of C5b-9.  IgG  did  not affect the 
distribution of C3 deposition on the O-Ag capsule and the outer membrane of 
12015, suggesting that bactericidal IgG was not directing complement activation 
to different sites on the bacterial surface. However, one-fifth of the C3 that was 
deposited in the presence of IgG attached covalently to the antibody molecule. 
Covalent complexes between purified C3b and IgG were prepared in order to 
study the role of C3b-IgG in the bactericidal reaction. 8-10-fold less C3b-IgG 
than IgG was necessary to sensitize  12015  for serum killing. When aggregates 
were eliminated from  the  C3b-IgG  and  IgG  preparations  by  sucrose density 
gradient ultracentrifugation, C3b-IgG remained three- to fourfold more effective 
than  IgG  on  a  molecule-for-molecule bound  basis  in  mediating  the  serum 888  BACTERICIDAL  ACTIVITY OF  C3b-IgG 
bactericidal  reaction.  These  results  suggest  that  formation of C3b-IgG during 
the serum bactericidal  reaction is critical  for killing,  and have important impli- 
cations for the development of effective bactericidal vaccines. 
Received for publication 25 March 1985 and in revised form  15 May 1985. 
References 
1.  Joiner,  K. A.,  R. C. Goldman, C. H. Hammer, L.  Leive, and M.  M.  Frank.  1983. 
Studies of the mechanism of bacterial resistance to complement-mediated killing. V. 
IgG and  F(ab')2  mediate  killing of E.  coli  011B4  by the  alternative  complement 
pathway without increasing C5b-9 deposition. J. Immunol.  131:2563. 
2.  Joiner,  K. A.,  M.  A. Schmetz, R. C. Goldman, L.  Leive, and M.  M.  Frank.  1984. 
Mechanism of bacterial resistance to complement-mediated killing:  inserted  C5b-9 
correlates with killing for Escherichia coli 0111B4 varying in O-antigen capsule and 
O-polysaccharide coverage of lipid A core oligosaccharide. Infect. Immun.  45:113. 
3.  Joiner,  K. A.,  R. C.  Goldman, C.  H. Hammer, L.  Leive, and M.  M.  Frank.  1983. 
Studies on the  mechanism of bacterial  resistance to complement-mediated killing, 
VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at 
a step before C5 cleavage. J. Immunol.  131:2570. 
4.  Goldman,  R.  C.,  D.  White,  and  F.  Orskov.  1982.  A  surface  polysaccharide  of 
Escherichia  coli  0111  contains  O-antigen and  inhibits agglutination  of cells by O- 
antiserum. J. Bacteriol.  151 : 1210. 
5.  Berger,  M., T. A. Gaither, R. M.  Cole, T. M.  Chused, C. H. Hammer, and M.  M. 
Frank. 1982. Biotinylation of human C3. Mol. lmmunol.  19:857. 
6.  Joiner, K. A., R. Goldman, M.  Schmetz, M.  Berger, C. H. Hammer, M.  M. Frank, 
and  L.  Leive.  1984.  A  quantitative analysis of C3  binding  to  O-antigen  capsule, 
lipopolysaccharide,  and  outer  membrane  protein  of E.  coli  01 l lB4. J.  Immunol. 
132:369. 
7.  Hammer, C.  H.,  G.  H. Wirtz,  L.  Renfer,  H.  D.  Gresham, and  B.  F.  Tack.  1981. 
Large scale isolation of functionally active components of the human complement 
system. J. Biol. Chem. 256:3995. 
8.  Joiner,  K.  A.,  C.  H.  Hammer, E. J.  Brown,  R. J.  Cole,  and  M.  M.  Frank.  1982. 
Studies on the mechanism of bacterial resistance to complement-mediated killing. I. 
Terminal  complement  components  are  deposited  and  released  from  Salmonella 
minnesota $218 without causing bacterial death. J. Exp. Med.  155:809. 
9.  Fries, L. F., T. A. Gaither, C. H. Hammer, and M.  M. Frank.  1984. C3b covalently 
bound to IgG demonstrates a reduced rate of inactivation by factors H and I.J. Exp. 
Med.  160:1640. 
10.  Gadd, K.J., and K. B. M. Reid.  1981. The binding of complement component C3 to 
antibody-antigen aggregates after activation of the  alternative pathway in human 
serum. Biochem. J.  195:471. 
11.  Takata, Y., N. Tamura, and T. Fugita. 1984. Interaction of C3 with antigen-antibody 
complexes  in  the  process  of  solubilization  of  immune  precipitates. J.  Immunol. 
132:2531. 
12.  Brown, E.J., M. Berger, K. A. Joiner, and M. M. Frank. 1983. Classical complement 
pathway activation by antipneumococcal antibodies leads to covalent binding of C3b 
to antibody molecules. Infect. Immun.  42:594. 
13.  Daha, M. R., D. T. Fearon, and K. F. Austen.  1976. C3 requirements for formation 
of alternative pathway C5 convertase. J. lmmunol.  117:630. 
14.  Medicus, R. G., O. G6tze, and H. J. Mfiller-Eberhard.  1976. Alternative pathway of JOINER  ET  AL.  889 
complement: recruitment of precursor properdin by the labile C3/C5 convertase and 
potentiation of the pathway. J. Exp. Med.  144:1076. 
15.  Joiner,  K.  A.,  M.  A.  Schmetz,  M.  E.  Sanders,  T.  G.  Murray,  C.  H.  Hammer, R. 
Dourmashkin, and M. M. Frank.  Multimeric C9 is necessary for killing of E. coli J5 
by C5b-9. Proc. Natl. Acad. Sci. USA. In press. 
16.  Hill, W., A. L. Shears, and K. G. Hibbit. 1978. The requirement of specific antibody 
for the killing of E.  coti by the alternative complement pathway in bovine serum. 
Immunology. 34:131. 
17.  Steele, E.J., and D. Rowley. 1977. The mechanism of complement fixation by rabbit 
F(ab')~: properties of the bactericidal reaction. Immunochemistry. 14:319. 
18.  Tarr, P.  I., S. W. Hosea, E. J. Brown, R. Schneerson, A. Sutton, and M. M. Frank. 
1982.  The  requirement  of  specific  anticapsular  IgG  for  killing  of Haemophilus 
influenzae by the alternative pathway of complement activation.J. Immunol.  128:1772. 
19.  Steele, N. P., R. S. Munson, D. M. Granoff, J. E. Cummins, and R. P. Levine. 1984. 
Antibody-dependent alternative pathway killing of Haemophilus  influenzae  type b. 
Infect. Immun.  44:452. 
20.  Moore,  F.  D.,  D. T.  Fearon, and K. F.  Austen.  1981.  IgG on mouse erythrocytes 
augments activation of the human alternative complement pathway by enhancing 
deposition of C3b. J. lmmunol.  126:1805. 
21.  Moore,  F.  D.,  K.  F.  Austen,  and  D.  T.  Fearon.  1982.  Antibody restores  human 
alternative complement pathway activation by mouse erythrocytes rendered  func- 
tionally deficient by pre-treatment with pronase. J. Immunol.  128:1302. 
22.  Schenkein, H. A., and S. Ruddy.  1981. The role of immunoglobulins in alternative 
pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative 
pathway.J. Immunol.  126:11. 
23.  Jacobs, R. J., and M. Reichlin.  1983. Generation of low M.W. C3-bearing immuno- 
globulin in human serum. J. Immunol.  130:2775. 
24.  Arnaout,  M.  A.,  N.  Dana, J.  Melamed, R.  Medicus, and H. R.  Colten.  1983.  Low 
ionic  strength  or  chemical  cross-linking of monomeric C3b  increases  its  binding 
affinity to the human complement C3b receptor. Immunology. 48:229. 